Cargando…

PB2267: COVID-19 OUTCOMES ON HAEMATOLOGY PATIENTS WHO RECEIVED RITUXIMAB: SINGLE CENTRE STUDY

Detalles Bibliográficos
Autores principales:	Hariharan, L., Champion-Homfray, M., Hassan, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429346/ http://dx.doi.org/10.1097/01.HS9.0000851896.06372.76

Ejemplares similares

PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)
por: Luminari, Stefano, et al.
Publicado: (2023)

PB2363: REPORTING LANGUAGE IN HAEMATOLOGICAL MALIGNANCIES
por: Watt, S., et al.
Publicado: (2022)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

PB2459: AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES OF HAEMATOLOGIC MALIGNANCIES COMPLICATED BY AUTOIMMUNE DISEASES
por: Kang, Ying, et al.
Publicado: (2023)

PB2545: HAEMATOLOGICAL INDICES IN DIFFERENTIAL DIAGNOSIS OF MICROCYTIC ANEMIAS, A REGIONAL STUDY
por: Myrtaj, Rialda, et al.
Publicado: (2023)

PB2240: TREATMENT OUTCOME OF CHRONIC MYELOMONOCYTIC LEUKEMIA; A SINGLE CENTRE EXPERIENCE FROM PAKISTAN
por: Anwar, Nida, et al.
Publicado: (2023)

PB2050: EVALUATION OF NON-CLONAL ERYTHROCYTOSIS: SINGLE CENTRE EXPERIENCE
por: Šumah, A., et al.
Publicado: (2022)

PB1714: DEXRAZOXANE IN HAEMATOLOGICAL PATIENTS: A META-ANALYSIS OF THE CARDIOPROTECTIVE EFFICACY, RISK OF SECONDARY MALIGNANCIES AND IMPACT IN SURVIVAL OUTCOMES
por: Pimenta, Mario Sousa, et al.
Publicado: (2023)

PB2192: THE IMPACT OF DENTAL DISEASE ON THE MANAGEMENT OF HAEMATOLOGICAL DISEASE: A REVIEW OF TWO CASES
por: Miles, E., et al.
Publicado: (2022)

PB2563: IRON DEFICIENCY ANEMIA: A MONOCENTRIC EXPERIENCE OF THE HAEMATOLOGY DEPARTMENT OF MONASTIR, TUNISIA
por: Bouhoula, Donia, et al.
Publicado: (2023)

PB2085: EPIDEMIOLOGICAL DESCRIPTION AND PROGNOSIS FEATURES OF MULTIPLE MYELOMA IN A TUNISIAN HAEMATOLOGY CENTER
por: Boughanmi, Sarah, et al.
Publicado: (2023)

PB2000: A COMPREHENSIVE NGS PANEL APPROACH FOR CLINICAL GENOMIC ANALYSIS IN HAEMATOLOGICAL MALIGNANCY
por: Mason, Joanne, et al.
Publicado: (2023)

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
por: Amorós, C., et al.
Publicado: (2022)

PB2071: INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA
por: Callejas Charavia, M., et al.
Publicado: (2022)

PB2652: EVALUATION OF 6 CASES WITH FXIII DEFICIENCY: SINGLE CENTRE EXPERIENCE
por: Sahin, Fahri, et al.
Publicado: (2023)

PB2039: INFLAMMATORY MARKERS IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS - A SINGLE CENTRE STUDY
por: Goubran, Mariam, et al.
Publicado: (2023)

PB2412: OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS–SINGLE CENTRE EXPERIENCE FROM PAKISTAN
por: Hussain, Mussawair, et al.
Publicado: (2023)

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.
por: Palomares, Laida Cuevas, et al.
Publicado: (2023)

PB2312: REACTIVATION OF HEPATITIS B VIRUS FOLLOWING RITUXIMAB IN B LYMPHOID HEMOPATHIES
por: Wafa, Miled, et al.
Publicado: (2023)

PB2610: EPIDEMIOLOGY AND TREATMENT OF ITP: A SINGLE CENTRE, REAL-WORLD EXPERIENCE
por: Patel, Priya, et al.
Publicado: (2023)

PB2348: THE PATIENT’S PERSPECTIVE ON CLNICAL TRIALS: RESULTS FROM A REGIONAL SURVEY IN HAEMATOLOGICAL CENTERS IN ANTWERP
por: Heyrman, B., et al.
Publicado: (2022)

PB2294: CHEMOTHERAPY INDUCED THROMBOCYTOPENIA AND ITS ASSOCITAION WITH COAGULOPATHY; A SINGLE CENTRE EXPERIENCE
por: ANWAR, N., et al.
Publicado: (2022)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
por: Mompel, O., et al.
Publicado: (2022)

PB2031: NEXT GENERATION SEQUENCING IN MYELOID NEOPLASMS: DEVELOPING WORLD DATA FROM SINGLE CENTRE
por: Anwar, Nida, et al.
Publicado: (2023)

PB1756: EPIDEMIOLOGY OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A RETROSPECTIVE 6-YEAR SINGLE CENTRE EXPERIENCE
por: Kociaj, Jora, et al.
Publicado: (2023)

PB2243: ROSAI-DORFMAN DISEASE -A SINGLE CENTRE EXPERIENCE OF A RARE HISTIOCYTIC DISORDER
por: Apperley, Harry, et al.
Publicado: (2023)

PB2676: ARE NOVEL THERAPEUTIC OPPORTUNITIES LEADING US TO OVERTREAT PATIENTS?: A REVIEW OF END-OF-LIFE SITUATION IN HAEMATOLOGICAL PATIENTS
por: Vázquez, Celia Martinez, et al.
Publicado: (2023)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022)

PB1937: A RARE, DIFFICULT- TO- DIAGNOSE DISEASE; LANGERHANS CELL HISTIOCYTOSIS – A SINGLE CENTRE EXPERIENCE
por: Tüzün, Betül Kübra, et al.
Publicado: (2023)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

PB1956: ANALYSIS OF CLINICAL COURSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMPLEX KARYOTYPE – SINGLE CENTRE EXPERIENCE
por: Sarac, Sofija, et al.
Publicado: (2023)

PB1733: LONG-TERM FOLLOW-UP FOR PATIENTS WITH T CELL LYMPHOBLASTIC LYMPHOMA/ ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED MODIFIED BFM PROTOCOLS
por: Gao, Yan, et al.
Publicado: (2023)

PB1751: RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R ALL) IN A SINGLE-CENTRE PAEDIATRIC POPULATION
por: Gomes, Guadalupe Ferreira, et al.
Publicado: (2023)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
por: Bai, J.-F., et al.
Publicado: (2022)

PB2315: EFFICACY AND SAFETY OF TWO DIFFERENT LOW-DOSE RITUXIMAB REGIMENS FOR CHINESE CHILDREN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
por: Zhu, X.
Publicado: (2022)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

PB2432: MULTIPLE MYELOMA TRANSPLANT DATABASE IN PATIENTS OVER THE AGE OF 65: A SINGLE CENTRE RETROSPECTIVE COHORT ANALYSIS
por: Tan, Janet, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9sbeoedird7c9k775vcl0riu5j